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580Objectives: We performed an investigation of the prognostic significance of the invasive component size,
excluding lepidic growth, in lung adenocarcinoma patients.
Methods: The data from 603 patients with completely resected pathologic stage I lung adenocarcinomas were
analyzed retrospectively to determine the relationship between pathologic tumor size and surgical results.
Results: The median tumor size of the total growth and the invasive component were 2.2 cm and 1.3 cm, respec-
tively. There were significant differences in recurrence-free survival between patients classified on the basis of
invasive component sizes (0.5 cm vs 0.5-2.0 cm, P<.001; and 0.5-2.0 cm vs>2.0 cm; P ¼ .026). A multi-
variate Cox regression analysis showed that invasive component size (P ¼ .002), age, sex, and lymphatic inva-
sion were independent prognostic factors for recurrence-free survival, whereas total tumor size was not
(P¼ .068). There were no significant differences in recurrence-free survival between patients who received ad-
juvant chemotherapy and those who did not in the group with invasive component size of 0.5 cm or less (P¼ .29)
and in the group with invasive component size of 0.5 to 2.0 cm (P¼ .50). However, the recurrence-free survival
of patients who received adjuvant chemotherapy was significantly better than that of those who did not in the
group with invasive component size greater than 2.0 cm (P ¼ .009).
Conclusions: Pathologic invasive component size, as opposed to total tumor size, is associated more
significantly with malignant behavior and prognosis and specifically should be considered before choosing can-
didates for adjuvant chemotherapy in pathologic stage I lung adenocarcinoma. (J Thorac Cardiovasc Surg
2013;146:580-5)Thewidespread use of low-dose helical computed tomogra-
phy (CT) for screening tumors has increased the early de-
tection of smaller non–small cell lung cancer (NSCLC),
particularly adenocarcinoma.1 Early lung adenocarcinomas
often contain a lepidic growth component.2-4 In small lung
adenocarcinoma, localized bronchioloalveolar carcinoma
(adenocarcinoma in situ [AIS]) without foci of active
fibroblastic proliferation showed no lymph node
metastasis and a favorable prognosis.2 We hypothesized
that the invasive component, not the lepidic growth compo-
nent, is associated with malignancy and prognosis in lung
adenocarcinoma. Therefore, we investigated and compared
the usefulness of invasive component size, excluding the
lepidic growth component, with that of the total tumore Department of surgical Oncology,a Department of Pathology,b Hiroshima
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The Journal of Thoracic and Cardiovascular Surgsize for determining the prognosis in patients with patho-
logic stage I lung adenocarcinoma. In addition, we exam-
ined the relationship between the adjuvant chemotherapy
effects and invasive component sizes.PATIENTS AND METHODS
Patients
We conducted a retrospective review of 603 consecutive cases of com-
pletely resected pathologic stage I lung adenocarcinomas from 2 institu-
tions (Hiroshima University and Hyogo Cancer Center, Japan) between
July 1, 2002, and December 31, 2011, to evaluate the significance of path-
ologic invasive component size. All patients who were staged according to
the TNM Classification of Malignant Tumours, 7th edition, underwent cu-
rative R0 resections.5 The inclusion criteria comprised curative surgery
without neoadjuvant chemotherapy or radiotherapy and a definitive histo-
pathologic diagnosis of lung adenocarcinoma. Patients with incompletely
resected tumors (R1 or R2) and those with multiple tumors or previous
lung surgery were excluded from the analysis. Segmentectomywas consid-
ered in patients with clinical stage IA tumor, which could be removed
completely with ample surgical margin. No lymph node metastasis was
confirmed intraoperatively using rapid frozen section for enlarged lymph
nodes or lymph nodes that were suspected to be diseased in the thoracic
cavity. When nodal metastasis was apparent or doubtful, lobectomy
was chosen instead. Systematic lymphadenectomy including hilar and
mediastinal node dissection can be performed in segmentectomy, but not
in wedge resection. Wedge resection therefore was performed for a tumor
that consisted mainly of a ground-glass opacity component on high-
resolution CT.ery c September 2013
TABLE 1. Patient characteristics
Variable n ¼ 603
Age, y, n (range) 67 (31-89)
Sex, n (%)
Male 306 (50.7)
Pathologic tumor size, n (range)
Total (cm) 2.2 (0.4-5.0)
Invasive component (cm) 1.3 (0-5.0)
p-Stage, n (%)
IA 416 (69.0)
IB 187 (31.0)
Lymphatic invasion, n (%)
Positive 124 (20.6)
Vascular invasion, n (%)
Positive 105 (17.4)
Pleural invasion, n (%)
Positive 97 (16.1)
Surgical procedure, n (%)
Pneumonectomy 1 (0.2)
Lobectomy 368 (61.0)
Segmentectomy 160 (26.5)
Wedge resection 74 (12.3)
Adjuvant chemotherapy, n (%)
Yes 141 (23.4)
Abbreviations and Acronyms
AIS ¼ adenocarcinoma in situ
AUC ¼ area under the curve
CT ¼ computed tomography
LY ¼ lymphatic invasion
MIA ¼ minimally invasive adenocarcinoma
NSCLC ¼ non–small cell lung cancer
PL ¼ pleural invasion
RFS ¼ recurrence-free survival
ROC ¼ receiver operating characteristic
V ¼ vascular invasion
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sion of the invasive component, excluding the lepidic growth component
described previously.6 In case the tumor was small, the invasive component
was measured under a microscope on a single slide. If the invasive compo-
nent could not be measured on a single slide under the microscope because
the tumor was large, then the invasive component size was calculated based
on multiplying the total tumor size by the percentage of the invasive com-
ponent. For example, if the total tumor size was assessed to be 4.0 cm by
standard gross measurement and the invasive component was estimated
to be 50% by pathologists, the invasive component size was determined
to be 2.0 cm. Adjuvant chemotherapy was considered for a patient whose
total tumor size was larger than 2 cm.
All patients who underwent lung resection were followed up from the
day of surgery. Postoperative follow-up procedures including a physical ex-
amination, a chest roentgenogram every 3 months, and chest and abdomi-
nal CT examinations every 6 months were performed for the first 2 years,
after which a physical examination and chest roentgenogram as well as
a chest CT examination were performed every 6 months and 1 year,
respectively.
This multicenter study was approved by the institutional review boards
of the participating institutions; both institutions waived the requirement
for informed consent from individual patients for this retrospective analysis
of the prospective database.
Statistical Analysis
Data are presented as numbers (percentages) or the median unless other-
wise stated. Pathologic malignant behavior was defined as positive lym-
phatic invasion (LY), vascular invasion (V), or pleural invasion (PL). To
evaluate the predicting values for pathologic malignant behavior, receiver
operating characteristic (ROC) curves of total tumor and invasive compo-
nent sizes were used and area under the curve (AUC) values were com-
pared. Recurrence-free survival (RFS) was defined as the interval
between the surgery date and the first event (relapse or death from any
cause) or the last follow-up visit. The RFS duration was analyzed using
the Kaplan–Meier method. Differences in RFS were assessed using the
log-rank test. A multivariate analysis with the Cox proportional hazards
model using variables with a P value less than .05 for univariate analysis
was used to assess the potential independent effects of pathologic tumor
size on RFS. A P value less than .05 was considered statistically significant.
The data were analyzed statistically using the Statistical Package for Social
Sciences software (version 10.5; SPSS, Chicago, Ill).RESULTS
The characteristics of the 603 study patients are summa-
rized in Table 1. The median follow-up period after surgeryThe Journal of Thoracic and Cawas 48.7 months, during which the tumor recurred in 78 pa-
tients (12.9%). The median size of the total tumor and its
invasive component was 2.2 cm and 1.3 cm, respectively.
LY, V, and PL were evident in 124 (20.6%), 105 (17.4%),
and 97 (16.1%) patients, respectively. A total of 141
(23.4%) patients underwent adjuvant chemotherapy and
131 (92.9%) of 141 patients had a total tumor size of greater
than 2 cm. The chemotherapy regimen comprised cisplatin
plus vinorelbine in 7 patients, carboplatin plus paclitaxel in
10 patients, gemcitabine plus tegafur–gimeracil–oteracil
potassium in 2 patients, gemcitabine in 1 patient, tegafur–
uracil in 94 patients, and tegafur–gimeracil–oteracil potas-
sium in 27 patients.
The total tumor size in 280 patients (46.4%) was 2 cm or
less, and in 323 patients (53.6%) was larger than 2 cm
(Table 2). With regard to invasive component size, 181
patients (30.0%) had a tumor measuring 0.5 cm or smaller,
a so-called AIS or minimally invasive adenocarcinoma
(MIA), 268 patients (44.4%) had a tumor measuring
0.5 to 2 cm, and 154 patients (25.5%) had a tumor measur-
ing larger than 2 cm.
Figure 1 shows the ROC curves of total tumor and in-
vasive component sizes for predicting the pathologic ma-
lignant behavior (LY, V, or PL). The AUC values of
total tumor and invasive component sizes were 0.673
(95% confidence interval [CI], 0.627-0.719) and 0.819
(95% CI, 0.786-0.852), respectively. The predictability
of pathologic malignant behavior based on the invasive
component size was better than that based on the total
tumor size.rdiovascular Surgery c Volume 146, Number 3 581
TABLE 2. Discrepancy between total tumor size and invasive
component size
Invasive component size
0.5 cm 0.5-2.0 cm >2.0 cm
Total tumor size, n
2.0 cm (n ¼ 280) 132 148
>2.0 cm (n ¼ 323) 49 120 154
Total (n ¼ 603) 181 268 154
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with an invasive component size of 0.5 cm or smaller
(5-year RFS rate, 96.6%), 0.5 to 2.0 cm (5-year RFS rate,
70.6%), and larger than 2.0 cm (5-year RFS rate, 62.2%)
(Figure 2).
The multivariate analysis included age, sex, pathologic
tumor size, LY, V, and PL. It showed that age, sex, inva-
sive component size, and LY were independent prognos-
tic factors for RFS, whereas total tumor size was not
(Table 3).
The adjuvant chemotherapy effects in each subgroup
based on invasive component size were investigated.
There were no differences in RFS between patients who
received adjuvant chemotherapy and those who did not
in the group with an invasive component size of 0.5 cm
or smaller (5-year RFS, 90.0% vs 97.1%; P ¼ .29)
(Figure 3, A) and 0.5 to 2.0 cm (5-year RFS, 77.9% vs
69.4%; P ¼ .50) (Figure 3, B). In contrast, there was a sig-
nificant difference in RFS between patients who received
adjuvant chemotherapy and those who did not in the
group with an invasive component size larger than
2.0 cm (5-year RFS, 78.6% vs 53.1%; P ¼ .009)
(Figure 3, C).FIGURE 1. ROC-AUC values of total tumor and invasive component sizes
invasive component size predicted the pathologic malignant behavior better tha
LY, lymphatic invasion; V, vascular invasion; PL, pleural invasion.
582 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Based on our hypothesis that the pathologic invasive
component, excluding the tumor lepidic growth, determines
malignancy and prognosis, we investigated the prognostic
significance of invasive component size compared with
that of total tumor size in patients with pathologic stage I
lung adenocarcinoma.
The ROC-AUC for predicting pathologic malignant be-
havior (LY, V, or PL) was considerably larger for the inva-
sive component size than for the total tumor size,
indicating that the size of the invasive component, not the
total tumor, reflects the pathologic malignant behavior.
With regard to RFS, multivariate Cox analysis showed
that the invasive component size and LY,which is a prognos-
tic factor for lung adenocarcinoma,7,8 were independent
prognostic factors but total tumor size was not, indicating
that the invasive component size more closely correlates
with survival than the total tumor size. Furthermore, we
divided the patients into 3 groups based on the invasive
component size with significant differences in RFS and
observed that patients with an invasive component size
smaller than 0.5 cm (AIS or MIA) had excellent
prognoses. Because invasive component size more closely
correlated with pathologic malignant behavior and
prognosis than total tumor size, invasive tumor size would
be suitable for the T-descriptor in TNM classification.
Several reports regarding the invasive component size in
lung adenocarcinoma have been published.6,9-11 One
report showed that mixed subtype with predominant
bronchioloalveolar carcinoma component in the 5-mm or
smaller invasive component group (MIA) as well as the
pure bronchioloalveolar carcinoma group (AIS) showed
no lymph node metastasis and excellent prognosis in earlyused for predicting pathologic malignant behavior (LY, V, or PL). The
n the total tumor size. CI, Confidence interval; AUC, area under the curve;
ery c September 2013
FIGURE2. Therewere significant differences in RFS among patients with an invasive component size of 0.5 cm or smaller (5-year RFS rate, 96.6%), 0.5 to
2.0 cm (5-year RFS rate, 70.6%), and larger than 2.0 cm (5-year RFS rate, 62.2%). RFS, Recurrence-free survival.
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invasive tumor size was associated more significantly with
disease-free survival than total tumor size.6 Our present
findings are consistent with these reports. In addition to
47.1% of T1a tumors, 15.2% of tumors more than 2 cm
were found to have an invasive component of 0.5 cm or
less. In total, 30.0% of pathologic stage I lung adenocarci-
noma patients belong to AIS orMIA, which shows excellent
prognosis after complete resection.
There are several implications of the updated adenocarci-
noma classification for staging that should be considered for
the next revision of the TNM classification.4 One is that the
total tumor size (T factor) may require a substitution of in-
vasive component size only. We previously reported that
solid tumor size on high-resolution CT was more usefulTABLE 3. Multivariate Cox regression analysis of RFS
Variable
Hazard ratio
(95% confidence interval) P value
Model 1
Age 1.05 (1.02-1.07) <.001
Sex (male) 2.02 (1.30-3.11) .002
Total tumor size (cm) 1.20 (.99-1.46) .068
Lymphatic invasion 2.98 (1.88-4.71) <.001
Vascular invasion 1.58 (0.96-2.61) .075
Pleural invasion 1.15 (0.71-1.86) .57
Model 2
Age 1.05 (1.03-1.07) <.001
Sex (male) 1.91 (1.24-2.96) .004
Invasive component size (cm) 1.30 (1.10-1.54) .002
Lymphatic invasion 2.74 (1.74-4.33) <.001
Vascular invasion 1.35 (0.81-2.24) .25
Pleural invasion 1.10 (0.68-1.77) .70
The Journal of Thoracic and Cafor predicting pathologic invasiveness, lymph node metas-
tasis, and prognosis than whole tumor size in clinical
stage IA lung adenocarcinoma.12-14 Clinically and
pathologically, the sizes of the solid or invasive
component using CT and pathology examinations are
more useful for predicting survival than those of the total
tumor. We strongly recommend that solid tumor size on
CT and invasive component size be used to determine the
T factor in the TNM classification of lung cancer.
Another interest is histologic subtype of adenocarcinoma
for predicting prognosis. The differences in substantial
survival among adenocarcinomas with aggressive (solid
or micropapillary), intermediate (acinar or papillary), or
indolent features (lepidic) were shown.15,16 Although this
study did not include histologic subtype data, in addition
to the histologic subtyping, invasive component size was
reported to be an independent prognostic factor in
pathologic stage I lung adenocarcinoma.6 Molecular re-
search studies including genomic, proteomic, or both also
have the potential to predict more accurate subclassification
of the malignant aggressiveness of adenocarcinoma.4 The
histologic subtype and molecular findings represent quality
of tumors whereas invasive component size represent quan-
tity of tumors. Further study is warranted to determine
which factors are suitable to be included in the T-factor
from the viewpoint of quality and quantity of the tumor.
Accurate staging that reflects prognosis is important to
select optimal patients for adjuvant chemotherapy. Adju-
vant chemotherapy for pathologic stage I NSCLC is con-
troversial.17 It has been suggested that platinum-based
adjuvant chemotherapy may benefit patients with tumors
4 cm or larger in stage IB NSCLC.18 Randomized phase
III trials and meta-analysis revealed that tegafur-uracilrdiovascular Surgery c Volume 146, Number 3 583
FIGURE 3. A, Therewere no differences in RFS between patients who received adjuvant chemotherapy and thosewho did not in the groupwith an invasive
component size of 0.5 cm or less (5-year RFS, 90.0% vs 97.1%; P ¼ .29). B, There were no differences in RFS between patients who received adjuvant
chemotherapy and those who did not in the group with an invasive component size of 0.5 to 2.0 cm (5-year RFS, 77.9% vs 69.4%; P ¼ .50). C, There was
a significant difference in RFS between patients who received adjuvant chemotherapy and thosewho did not in the group with an invasive component size of
larger than 2.0 cm (5-year RFS, 78.6% vs 53.1%; P ¼ .009). RFS, Recurrence-free survival.
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NSCLC, particularly lung adenocarcinomas larger than
2 cm.19-21 Selecting optimal patients who would benefit
from adjuvant chemotherapy can prevent unnecessary
chemotherapy. We evaluated the effect of adjuvant
chemotherapy in each subgroup divided on the basis of
invasive component size. In this study, patients with an
invasive tumor size of 2 cm or less did not benefit from
adjuvant chemotherapy, whereas those with an invasive
tumor size larger than 2 cm did. Although 92.9% of
patients who underwent adjuvant chemotherapy had
a total tumor size larger than 2 cm, approximately 50%
of these patients had an invasive component 2 cm or
smaller. Therefore, candidates for adjuvant chemotherapy
in stage I lung adenocarcinoma should be selected on
the basis of invasive component size. Patients with AIS584 The Journal of Thoracic and Cardiovascular Surgor MIA and also those with an invasive component size
of 0.5 to 2 cm would not benefit from adjuvant
chemotherapy.
The retrospective nature of the analysis was a limitation
of this study. Therefore, prospective studies are required to
evaluate the effects of adjuvant chemotherapy for each pa-
tient group subdivided on the basis of invasive component
size.
In conclusion, invasive component size, excluding lepi-
dic growth, has a higher predictive value for pathologic ma-
lignant behavior and prognosis than total tumor size and
aids in selecting optimal candidates for adjuvant chemo-
therapy among patients with pathologic stage I lung adeno-
carcinoma. We highly recommend using invasive
component size as the new T descriptor in TNM classifica-
tion of lung cancer.ery c September 2013
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